Pharmaceutical Technology on MSN16h
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
The Pharma Letter1d
Galderma wins EU twin approvals for Nemluvio
Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
Hosted on MSN2mon
FDA approves Galderma’s Nemluvio to treat atopic dermatitis
The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for individuals aged 12 years and over with moderate-to-severe atopic dermatitis.
pharmaphorum2mon
Galderma adds new indication for blockbuster hope Nemluvio
Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in ...
Mirage News1d
EU Greenlights Galderma's Nemluvio for Skin Conditions
Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...
pharmaphorum6mon
Galderma gets FDA nod for prurigo nodularis therapy
Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. The US regulator cleared the IL-31 ...
Yahoo Finance1mon
GALDERMA GROUP AG (GALDY)
ZUG, Switzerland, December 13, 2024--Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of ...